- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Berotralstat reduces overall disease burden in hereditary angioedema: Study
USA: In a new study conducted by Emel Aygoren-Pursun and team, it was found that berotralstat, regardless of baseline attack rate, is an effective oral preventive therapy option that can minimize disease burden against hereditary angioedema (HAE). The findings of this study were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting.
It is well established that lowering attack rates reduces the overall illness burden of people with HAE. Prophylactic HAE therapy aims to lessen the disease burden by lowering attack rates. Berotralstat is a preventive once-daily (QD) therapy for HAE. The long-term effectiveness of berotralstat 150mg in patients who finished 96 weeks of therapy in the APeX-2 trial (NCT03485911), stratified by baseline attack rate, has been published in this study.
For 24 weeks, patients were randomly assigned to berotralstat (110mg or 150mg) or placebo QD. Patients assigned to berotralstat stayed on the same dose at Week 24, while placebo patients were rerandomized to berotralstat for a further 24 weeks; following Week 48, all patients remained on berotralstat 150mg. Twenty-one individuals received berotralstat 150mg for a total of 96 weeks. This study divided patients into tertiles based on their baseline attack rate: Group 1: 2 attacks per month; Group 2: 2 to 3 attacks per month; Group 3: 3 attacks per month.
The results of this study stated as follow:
1. The mean (SEM) monthly assault rate in Group 1 (n57) decreased from 1.2(0.1) at baseline to 0.3(0.2) at Week 24, 0.1(0.1) at Week 48, and 0 at Week 96.
2. In Group 2 (n57), the mean monthly assault rate fell from 2.6(0.2) at baseline to 1.1(0.5) at Week 24, 0.1(0.1) at Week 48, and 0.3(0.2) at Week 96.
3. The mean attack rate in Group 3 (n57) decreased from 4.6(0.6) at baseline to 1.7(0.8) at Week 24, 1.6(0.6) at Week 48, and 0.7(0.4) at Week 96.
4. Over 70% of patients in each tertile saw a >70% relative reduction in attack rate.
In conclusion, regardless of the baseline attack rate, berotralstat is a primary oral preventive therapy option that can minimize disease burden by reducing HAE-related deficits.
Reference:
Aygoren-Pursun E, McNeil D, Collis P, et al. Oral Berotralstat Treatment for 96 Weeks Consistently Reduces Hereditary Angioedema (HAE) Attack Rates Regardless of Baseline Attack Rate. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting; February 25–28, 2022; Phoenix, AZ. Abstract 491.
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751